Clinical Trial Update: Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Sacituzumab Tirumotecan in recurrent or metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma; the study is not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma
• Papillary Thyroid Carcinoma

Drugs mentioned

• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: Recurrent Adenoid Cystic Carcinoma, Adenoid Cystic Carcinoma Metastatic | Phase 2 | Status: NOT_YET_RECRUITING